Shanghai Changzheng Hospital
Clinical trials sponsored by Shanghai Changzheng Hospital, explained in plain language.
-
Front vs back surgery: which is better for stiff spine condition?
Disease control OngoingThis study compares two surgical approaches for severe ossification of the posterior longitudinal ligament (OPLL), a condition where a ligament in the spine hardens and presses on the spinal cord. One surgery (ACAF) goes through the front of the neck to remove the hardened ligame…
Phase: NA • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Experimental cell therapy targets Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase trial tests a new type of immune cell therapy (PSMA-UCAR T cells) in 3 men with advanced prostate cancer that no longer responds to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants must have me…
Phase: PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Engineered immune cells take on hard-to-treat prostate cancer
Disease control OngoingThis early-phase trial tests whether a patient's own immune cells, modified to target a protein called PSMA on prostate cancer cells, are safe and can shrink tumors or lower PSA levels. It involves 7 to 18 men with metastatic castration-resistant prostate cancer that has stopped …
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New antibody combo aims to control hard-to-treat prostate cancer
Disease control OngoingThis early-stage trial tests whether combining two antibodies (anti-IGF-1R and anti-PD-1) can safely control metastatic castration-resistant prostate cancer (mCRPC) — a type that has stopped responding to hormone therapy. Seven men with advanced disease will receive the combinati…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC